Grupo Espanol de trasplantes hematopoyeticos y terapia celular

Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers

Role: lead

Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors

Role: collaborator

CAR-T Cell Therapy in Patients With Hematological Malignancies

Role: lead

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Role: lead

Aspergillus PCR Early Detection in High Risk Oncohematological Patients

Role: lead

Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease

Role: lead

Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT

Role: lead

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

Role: lead

Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.

Role: lead

Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH

Role: lead